Dosing frequency and adherence in chronic psychiatric disease: Systematic review and meta-analysis

Neuropsychiatric Disease and Treatment

Volumn 9, Issue 1, 2012, Pages 119-131

  Medic, Goran ^a   Higashi, Kyoko ^a   Littlewood, Kavi J ^a   Diez, Teresa ^b   Granström, Ola ^c   Kahn, René S ^d  

^a MAPI GROUP   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adherence; Depression; Dosing frequency; Epilepsy; Schizophrenia

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; PHENOBARBITAL; PHENYTOIN;

ATTITUDE TO ILLNESS; BIPOLAR DISORDER; CLINICAL ASSESSMENT TOOL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REGIMEN; EPILEPSY; HUMAN; MAJOR DEPRESSION; MEDICATION EVENT MONITORING SYSTEM; MEDICATION PERSISTENCE; MEDICATION POSSESSION RATIO; MENTAL DISEASE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PSYCHOSIS; REFILL ADHERENCE; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84872866623     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S39303     Document Type: Review

References (37)

1. Wu EQ, Birnbaum HG, Shi L, etal. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66: 1122-1129.
2. Hovinga CA, Asato MR, Manjunath R, etal. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav. 2008;13:316-322.
3. Baker GA, Jacoby A, Buck D, etal. Quality of life of people with epilepsy: a European study. Epilepsia. 1997;38:353-362.
4. Andrade L, Caraveo-Anduaga JJ, Berglund P, etal. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res. 2003;12:3-21.
5. Kessler RC, Berglund P, Demler O, etal. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
6. Cramer JA, Roy A, Burrell A, etal. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44-47.
7. Kelin K, Lambert T Jr, Brnabic AJ, etal. Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence. Patient Prefer Adherence. 2011;5:213-222.
8. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 2008;161:235-247.
9. Chen EY, Hui CL, Dunn EL, etal. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr Res. 2005;77:99-104.
10. Eatock J, Baker GA. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr Dis Treat. 2007;3:117-131.
11. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008;49:446-454.
12. Ettinger AB, Manjunath R, Candrilli SD, etal. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav. 2009;14:324-329.
13. Faught E, Duh MS, Weiner JR, etal. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study. Neurology. 2008;71:1572-1578.
14. Liu X, Chen Y, Faries DE. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. Clinicoecon Outcomes Res. 2011;3:63-72.
15. Cramer JA, Mattson RH, Prevey ML, etal. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261: 3273-3277.
16. Remington G, Kwon J, Collins A, etal. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res. 2007;90:229-237.
17. Diaz E, Neuse E, Sullivan MC, etal. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry. 2004;65:354-360.
18. Byerly M, Fisher R, Whatley K, etal. A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005;133:129-133.
19. McLaughlin T, Hogue SL, Stang PE. Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression. Am J Ther. 2007;14:221-225.
20. Pfeiffer PN, Ganoczy D, Valenstein M. Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv. 2008;59:1207-1210.
21. Stang P, Young S, Hogue S. Better patient persistence with once-daily bupropion compared with twice-daily bupropion. Am J Ther. 2007;14:20-24.
22. Stang P, Suppapanaya N, Hogue SL, etal. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population. Am J Ther. 2007;14:241-246.
23. Bies RR, Gastonguay MR, Coley KC, etal. Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques. Am J Geriatr Psychiatry. 2002;10:696-705.
24. de Klerk E. Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry. 2001;62:43-47.
25. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord. 2004;19:513-517.
26. Bova CA, Fennie KP, Knafl GJ, etal. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav. 2005;9:103-110.
27. McKenney JM, Munroe WP, Wright JT Jr. Impact of an electronic medication compliance aid on long-term blood pressure control. J Clin Pharmacol. 1992;32:277-283.
28. Shemesh E. Non-adherence to medications following pediatric liver transplantation. Pediatr Transplant. 2004;8:600-605.
29. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0; 2011. Available from: http://www.cochrane-handbook.org/. Accessed November 23, 2011.
30. NICE Decision Support Unit. Available from: http://www.nicedsu.org.uk/Technical-Support-Documents(1985314).htm. Accessed November 23, 2011.
31. Doughty J, Baker GA, Jacoby A, etal. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav. 2003;4:710-716.
32. Zaccara G, Galli A. Effectiveness of simplified dosage schedules on the management of ambulant epileptic patients. Eur Neurol. 1979;18: 341-344.
33. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3:338-342.
34. Meier J, Becker T, Patel A, etal. Effect of medication-related factors on adherence in people with schizophrenia: a European multi-centre study. Epidemiol Psichiatr Soc. 2010;19:251-259.
35. Saini SD, Schoenfeld P, Kaulback K, etal. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22-e33.
36. Andersson K, Melander A, Svensson C, etal. Repeat prescriptions: refill adherence in relation to patient and prescriber characteristics, reimbursement level and type of medication. Eur J Public Health. 2005;15:621-626.
37. Krigsman K, Melander A, Carlsten A, etal. Refill non-adherence to repeat prescriptions leads to treatment gaps or to high extra costs. Pharm World Sci. 2007;29:19-24.